Literature DB >> 30606323

Number and cost of hospitalizations with principal and secondary diagnoses of tuberculosis, United States.

M V Aslam1, K Owusu-Edusei1, S M Marks1, G R B Asay1, R Miramontes1, M Kolasa1, C A Winston1, P M Dietz1.   

Abstract

OBJECTIVE: To estimate the number and cost of hospitalizations with a diagnosis of active tuberculosis (TB) disease in the United States.
METHODS: We analyzed the 2014 National In-Patient Sample using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) codes to identify hospitalizations with a principal (TB-PD) or any secondary discharge (TB-SD) TB diagnosis. We used a generalized linear model with log link and gamma distribution to estimate the cost per TB-PD and TB-SD episode adjusted for patient demographics, insurer, clinical elements, and hospital characteristics.
RESULTS: We estimated 4985 TB-PD and 6080 TB-SD hospitalizations nationwide. TB-PD adjusted averaged $16 695 per episode (95%CI $16 168-$17 221). The average for miliary/disseminated TB ($22 498, 95%CI $21 067-$23 929) or TB of the central nervous system ($28 338, 95%CI $25 836-$30 840) was significantly greater than for pulmonary TB ($14 819, 95%CI $14 284-$15 354). The most common principal diagnoses for TB-SD were septicemia (n = 965 hospitalizations), human immunodeficiency virus infection (n = 610), pneumonia (n = 565), and chronic obstructive pulmonary disease and bronchiectasis (COPD-B, n = 150). The adjusted average cost per TB-SD episode was $15 909 (95%CI $15 337-$16 481), varying between $8687 (95%CI $8337-$9036) for COPD-B and $23 335 (95%CI $21 979-$24 690) for septicemia. TB-PD cost the US health care system $123.4 million (95%CI $106.3-$140.5) and TB-SD cost $141.9 million ($128.4-$155.5), of which Medicaid/Medicare covered respectively 67.2% and 69.7%.
CONCLUSIONS: TB hospitalizations result in substantial costs within the US health care system.

Entities:  

Mesh:

Year:  2018        PMID: 30606323      PMCID: PMC8050949          DOI: 10.5588/ijtld.18.0260

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  11 in total

1.  Treatment of tuberculosis.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2003-06-20

2.  Tuberculosis hospitalization expenditures per patient from private health insurance claims data, 2010-2014.

Authors:  K Owusu-Edusei; S M Marks; R Miramontes; E L Stockbridge; C A Winston
Journal:  Int J Tuberc Lung Dis       Date:  2017-04-01       Impact factor: 2.373

3.  Health-care expenditures for tuberculosis in the United States.

Authors:  R E Brown; B Miller; W R Taylor; C Palmer; L Bosco; R M Nicola; J Zelinger; K Simpson
Journal:  Arch Intern Med       Date:  1995 Aug 7-21

4.  Causes and costs of hospitalization of tuberculosis patients in the United States.

Authors:  Z Taylor; S M Marks; N M Ríos Burrows; S E Weis; R L Stricof; B Miller
Journal:  Int J Tuberc Lung Dis       Date:  2000-10       Impact factor: 2.373

Review 5.  Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA.

Authors:  Philip A LoBue; Jonathan H Mermin
Journal:  Lancet Infect Dis       Date:  2017-05-08       Impact factor: 25.071

6.  Hospital costs in the US for pulmonary mycobacterial diseases.

Authors:  Mehdi Mirsaeidi; Mary Beth Allen; Golnaz Ebrahimi; Dean Schraufnagel
Journal:  Int J Mycobacteriol       Date:  2015-09

7.  Professional Fee Ratios for US Hospital Discharge Data.

Authors:  Cora Peterson; Likang Xu; Curtis Florence; Scott D Grosse; Joseph L Annest
Journal:  Med Care       Date:  2015-10       Impact factor: 2.983

Review 8.  Directly observed therapy for treating tuberculosis.

Authors:  Jamlick Karumbi; Paul Garner
Journal:  Cochrane Database Syst Rev       Date:  2015-05-29

9.  Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007.

Authors:  Suzanne M Marks; Jennifer Flood; Barbara Seaworth; Yael Hirsch-Moverman; Lori Armstrong; Sundari Mase; Katya Salcedo; Peter Oh; Edward A Graviss; Paul W Colson; Lisa Armitige; Manuel Revuelta; Kathryn Sheeran
Journal:  Emerg Infect Dis       Date:  2014-05       Impact factor: 6.883

10.  Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement.

Authors:  Kirsten Bibbins-Domingo; David C Grossman; Susan J Curry; Linda Bauman; Karina W Davidson; John W Epling; Francisco A R García; Jessica Herzstein; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; William R Phillips; Maureen G Phipps; Michael P Pignone
Journal:  JAMA       Date:  2016-09-06       Impact factor: 56.272

View more
  3 in total

1.  Predictors for Pulmonary Tuberculosis Outcome and Adverse Events in an Italian Referral Hospital: A Nine-Year Retrospective Study (2013-2021).

Authors:  Francesco Di Gennaro; Rossana Lattanzio; Giacomo Guido; Aurelia Ricciardi; Roberta Novara; Giulia Patti; Sergio Cotugno; Elda De Vita; Gaetano Brindicci; Michele Fabiano Mariano; Luigi Ronga; Carmen Rita Santoro; Federica Romanelli; Stefania Stolfa; Roberta Papagni; Davide Fiore Bavaro; Giusi De Iaco; Annalisa Saracino
Journal:  Ann Glob Health       Date:  2022-04-26       Impact factor: 3.640

Review 2.  Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States.

Authors:  Amit S Chitnis; Ramsey Cheung; Robert G Gish; Robert J Wong
Journal:  J Immigr Minor Health       Date:  2021-06-23

3.  Burden of Active Tuberculosis in an Integrated Health Care System, 1997-2016: Incidence, Mortality, and Excess Health Care Utilization.

Authors:  Paul Y Wada; Christian Lee-Rodriguez; Yun-Yi Hung; Jacek Skarbinski
Journal:  Open Forum Infect Dis       Date:  2020-01-12       Impact factor: 3.835

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.